Study data presented at tvt on the economics of minimalist tavr, partner 3 bicuspid tavr

Irvine, calif., july 22, 2021 /prnewswire/ -- edwards lifesciences (nyse: ew) today announced that clinical and economic results from the 3m (multidisciplinary, multimodality, but minimalist) transcatheter aortic valve replacement (tavr) economic study and the partner 3 bicuspid registry for sapien 3 tavr study were presented at tvt 2021: the structural heart summit.
EW Ratings Summary
EW Quant Ranking